Federal Circuit Upholds Stringent Requirements for Antibody Patent Descriptions

In a recent ruling, the Federal Circuit upheld a decision from the U.S. Patent and Trademark Office (USPTO) regarding an antibody patent application. The court concluded that the preambles for Jepson claims require adequate written descriptions. This decision has significant implications for patent applications in biotechnology and life sciences, emphasizing the necessity for clarity in claim preambles. For further details, the original article is available on Law360.